Replimune Group Inc (OQ:REPL)

Business Focus: Biotechnology & Medical Research

Apr 07, 2024 05:00 pm ET
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Asso
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial...
Apr 04, 2024 08:00 am ET
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the grant of inducement equity awards to Carolyn Trott, the Company’s newly...
Mar 26, 2024 07:30 am ET
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s...
Mar 06, 2024 08:00 am ET
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced presentations at the upcoming American Association for Cancer Research (AACR)...
Mar 05, 2024 08:00 am ET
Replimune to Present at Three Upcoming Investor Conferences
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor...
Feb 08, 2024 08:00 am ET
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and...
Jan 16, 2024 02:59 am ET
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets.Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer.Experienced team of individuals with expertise in surface proteomics and oncology from academia, biotech and pharma, led by CEO Roman Thomas.Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.COLO
Dec 28, 2023 08:00 am ET
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at...
Dec 05, 2023 07:00 am ET
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed M
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced results from the primary analysis of the CERPASS trial evaluating RP1 in...
Nov 08, 2023 09:10 am ET
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in...
Nov 07, 2023 08:00 am ET
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and...
Nov 03, 2023 07:30 pm ET
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating...
Sep 19, 2023 04:01 pm ET
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly...
Sep 19, 2023 08:00 am ET
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most...
Aug 03, 2023 08:00 am ET
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30,...
Aug 01, 2023 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
Jul 31, 2023 04:01 pm ET
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.
Jul 20, 2023 08:00 am ET
Replimune Announces Sander Slootweg will Depart from its Board of Directors
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Sander Slootweg, founder and managing partner at Forbion, will not...
Jun 06, 2023 10:00 am ET
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced initial data from ARTACUS, a Phase 1/2 trial evaluating RP1 for...
Jun 05, 2023 08:00 am ET
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company’s...
Jun 03, 2023 02:15 pm ET
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced updated data from the first 75 patients in the anti-PD1 failed...
Jun 01, 2023 04:01 pm ET
Replimune to Present at the Jefferies Global Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
May 25, 2023 05:00 pm ET
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical...
May 18, 2023 08:00 am ET
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended...
May 09, 2023 08:00 am ET
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will host...
Mar 08, 2023 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
Feb 09, 2023 08:00 am ET
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December...
Feb 07, 2023 08:00 am ET
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of...
Jan 04, 2023 08:05 am ET
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), today announced the grant of inducement equity awards to Chris Sarchi, the...
Jan 04, 2023 08:00 am ET
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune’s Chief...
Jan 03, 2023 08:00 am ET
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune,...
Dec 08, 2022 09:04 pm ET
Replimune Announces Pricing of Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its...
Dec 07, 2022 04:04 pm ET
Replimune Announces Proposed Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common...
Dec 07, 2022 07:00 am ET
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the...
Dec 07, 2022 06:30 am ET
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that the Company has entered into a Master Clinical Trial...
Nov 23, 2022 08:00 am ET
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside...
Nov 22, 2022 08:00 am ET
Replimune to Host Virtual Investor Event on December 7, 2022
Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor event to...
Nov 03, 2022 08:00 am ET
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September...
Nov 02, 2022 04:01 pm ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and...
Oct 07, 2022 08:00 am ET
Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan...
Aug 04, 2022 08:00 am ET
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2022...
Aug 01, 2022 04:01 pm ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and...
Jun 03, 2022 08:00 am ET
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from the...
Jun 02, 2022 08:00 am ET
Replimune to Present at the Jefferies Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside...
May 26, 2022 05:15 pm ET
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical...
May 19, 2022 08:00 am ET
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended...
Mar 30, 2022 07:00 am ET
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced updated data from completed cohorts of the Phase 2 part of the...
Mar 21, 2022 08:00 am ET
Replimune to Host Virtual Investor Event on March 30, 2022
Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders will...
Feb 11, 2022 08:00 am ET
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune,...
Feb 03, 2022 08:00 am ET
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31,...
Jan 31, 2022 04:01 pm ET
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the...
Jan 10, 2022 07:00 am ET
Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today provided a corporate update, highlighting the progress of key programs....
Jan 04, 2022 08:00 am ET
Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune,...
Dec 02, 2021 08:00 am ET
Replimune Appoints Christy Oliger to its Board of Directors
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors...
Nov 12, 2021 07:00 am ET
Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data from RP2 alone and in combination with Opdivo...
Nov 04, 2021 08:00 am ET
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced financial results for the fiscal second quarter ended September 30, 2021 and provided a...
Nov 01, 2021 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings...
Oct 01, 2021 08:01 am ET
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC)...
Aug 06, 2021 08:00 am ET
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced financial results for the fiscal first quarter ended June 30, 2021 and provided a...
Aug 02, 2021 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings...
Jul 07, 2021 08:00 am ET
Replimune to Present at the William Blair Biotech Focus Conference 2021
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of...
Jun 03, 2021 07:00 am ET
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced updated interim data from the Phase 2 skin cancer cohorts combining RP1 (vusolimogene...
May 20, 2021 08:00 am ET
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced financial results for the fiscal fourth quarter and year ended March 31, 2021...
May 10, 2021 08:00 am ET
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced the strengthening of its executive team with the appointment of Tanya Lewis to a newly...
May 05, 2021 07:00 am ET
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized...
Apr 28, 2021 08:00 am ET
Replimune to Host Virtual Investor Event on June 3, 2021
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced it will host an investor event to present updated data from its Phase 2 skin cancer...
Apr 21, 2021 08:00 am ET
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the appointment of Sushil Patel, Ph.D. as...
Apr 12, 2021 04:01 pm ET
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced additional data supporting the multiple mechanisms of action for its lead programs, RP1...
Mar 11, 2021 04:01 pm ET
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR)...
Mar 04, 2021 08:00 am ET
Replimune to Present at Three Upcoming Investor Conferences
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings...
Feb 18, 2021 08:00 am ET
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the SVB...
Feb 04, 2021 08:00 am ET
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal third quarter ended December 31, 2020 and provided a...
Jan 11, 2021 07:00 am ET
Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, provides corporate update, highlighting the progress of its key programs. “Replimune made great progress...
Jan 06, 2021 08:00 am ET
Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th...
Jan 05, 2021 08:00 am ET
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced it has dosed the first patient in a Phase 1, open-label, dose-escalation and expansion clinical...
Nov 12, 2020 08:00 am ET
Replimune to Participate at the SVB Leerink Oncology 1x1 Day
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will host investor meetings at the at the SVB...
Nov 09, 2020 08:00 am ET
Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that the posters being presented at the Society for Immunotherapy of Cancer (SITC) annual...
Nov 05, 2020 08:00 am ET
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal second quarter ended September 30, 2020 and provided a...
Oct 22, 2020 01:09 am ET
Replimune Announces Pricing of Upsized Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 4,687,500 shares of its common stock at a public...
Oct 20, 2020 04:02 pm ET
Replimune Announces Proposed Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of $125 million of shares of its common stock. All shares of...
Oct 20, 2020 04:01 pm ET
Replimune Releases Updated Corporate Presentation
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that it is filing a Current Report on Form 8-K with the Securities and Exchange Commission...
Oct 19, 2020 04:01 pm ET
Replimune Appoints Tanya Lewis to the Board of Directors
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2,...
Oct 14, 2020 12:28 pm ET
Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the Company’s lead product candidate, RP1, along with initial single agent safety...
Oct 01, 2020 07:00 am ET
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will present in a fireside chat and host...
Aug 07, 2020 07:00 am ET
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal first quarter ended June 30, 2020 and provided a...
Aug 04, 2020 07:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host investor meetings at...
Jul 22, 2020 07:00 am ET
Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the appointment of Andrea Pirzkall, M.D. as...
Jun 17, 2020 08:00 am ET
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a...
Jun 08, 2020 11:21 pm ET
Replimune Announces Pricing of Upsized Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 2,826,088 shares of its common stock at a public...
Jun 08, 2020 04:16 pm ET
Replimune Announces Proposed Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of $80 million of shares of its common stock and, in lieu of...
Jun 03, 2020 07:15 am ET
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal fourth quarter and year ended March 31, 2020...
Jun 03, 2020 07:00 am ET
Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced new interim data presented from the Phase 2 part of its Phase 1/2 clinical trial of RP1...
Apr 30, 2020 06:00 am ET
Replimune to Provide Data Update on June 3, 2020
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host a conference call to provide updated data from patients with melanoma and...
Apr 02, 2020 07:00 am ET
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new...
Feb 13, 2020 07:00 am ET
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today provided a corporate update, highlighting the progress of its key programs. “Based on the early...
Feb 06, 2020 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will participate in fireside chats and...
Jan 13, 2020 07:00 am ET
Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today provided a corporate update, highlighting the progress of its key programs. “Replimune had a very...
Jan 09, 2020 07:00 am ET
Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the evolution of the responsibilities within its executive leadership team, reflecting the...
Jan 07, 2020 08:00 am ET
Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present...
Dec 09, 2019 08:00 am ET
Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the expansion of its executive team with the appointment of Jean M. Franchi as Chief...
Nov 26, 2019 08:00 am ET
Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and...
Nov 14, 2019 06:22 am ET
Replimune Announces Pricing of Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its public offering of 3,678,031 shares of its common stock at a public...
Nov 12, 2019 04:06 pm ET
Replimune Announces Proposed Public Offering
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public offering of up to 5,000,000 shares of its common stock. All shares in...
Nov 11, 2019 08:00 am ET
Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for its second fiscal quarter, ended September 30, 2019, and provided a...
Nov 08, 2019 07:30 am ET
 Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, will today present data from the Phase 1 part of its Phase 1/2 clinical trial of RP1 as monotherapy and...
Oct 31, 2019 04:00 pm ET
Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host an investor event to review the full safety, clinical efficacy, and biomarker...
Oct 24, 2019 08:00 am ET
Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that the company has enrolled the first patient in its Phase 1 clinical trial of RP2. RP2...
Oct 15, 2019 07:00 am ET
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that the first patient has been enrolled in its registration-directed, randomized,...
Oct 02, 2019 08:00 am ET
Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the Company’s lead product candidate, RP1, will be presented at the upcoming...
Oct 01, 2019 08:00 am ET
Replimune to Present at Chardan’s 3rd Annual Genetic Medicines Conference
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will...
Aug 14, 2019 08:00 am ET
Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for its first fiscal quarter, ended June 30, 2019, and provided an...
Aug 06, 2019 08:00 am ET
Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and...
Jun 28, 2019 08:00 am ET
Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for its fourth fiscal quarter and year ended March 31, 2019, and...
Jun 01, 2019 09:00 am ET
Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that the Phase 2 portion of the Company’s Phase 1/2 clinical trial of RP1 alone and in...
May 30, 2019 08:00 am ET
Replimune to Present at Upcoming Investor Conferences
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team, will present and host investor meetings at...
May 16, 2019 07:00 am ET
Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that a trial in progress (TiP) poster will be presented at the 2019 American Society of...
Apr 01, 2019 07:00 am ET
Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that pre-clinical data on its oncolytic immunotherapy platform will be presented at a...
Feb 14, 2019 08:00 am ET
Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for its third fiscal quarter ended December 31, 2018, and provided an...
Feb 07, 2019 08:00 am ET
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will participate...
Jan 03, 2019 08:00 am ET
Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced status updates highlighting progress with the Company’s key programs.  “Replimune had a...
Dec 20, 2018 08:00 am ET
Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present at...
Dec 05, 2018 08:00 am ET
Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present at...
Nov 14, 2018 08:00 am ET
Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced financial results for its second fiscal quarter ended September 30, 2018, and provided an update...
Sep 26, 2018 08:00 am ET
Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will present at...
Sep 06, 2018 04:01 pm ET
Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug...
Aug 30, 2018 08:00 am ET
Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update
Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced financial results for its first fiscal quarter ended June 30, 2018, and provided an update on...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.